Cargando…
Concurrent malignant melanoma and cutaneous involvement by classical hodgkin lymphoma (CHL) in a 63 year-old man
ABSTRACT: Classical Hodgkin lymphoma (CHL) is a lymphoproliferative disorder that has a bimodal age distribution, affecting young and elderly individuals, and is curable in more than 90% of patients. Here we report the coexistence of cutaneous CHL and malignant melanoma as the presentation of papule...
Autores principales: | Gru, Alejandro A, Lu, Dongsi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765467/ https://www.ncbi.nlm.nih.gov/pubmed/23938065 http://dx.doi.org/10.1186/1746-1596-8-135 |
Ejemplares similares
-
P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022) -
Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015) -
P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
por: Piperidou, Alexia, et al.
Publicado: (2022) -
Impact of Tumour Epstein–Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL
por: Nohtani, Mahdi, et al.
Publicado: (2022) -
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
por: Rajabto, Wulyo, et al.
Publicado: (2022)